PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide that acts as a melanocortin receptor agonist. Research has examined its activity across melanocortin receptor subtypes, particularly MC1R and MC4R, and its involvement in central nervous system and neuroendocrine signaling.

Bremelanotide is also an FDA-approved prescription drug under the brand name Vyleesi for a specific indication involving acquired, generalized hypoactive sexual desire disorder in premenopausal women. It is not indicated to enhance sexual performance or for use in men or postmenopausal women.

For research applications, PT-141 can be used as a compound for investigating melanocortin receptor pharmacology, central signaling, and related neuroendocrine pathways under controlled laboratory conditions.